Leaderboard

En | De
No articles selected!     View Cart  
You are here: Urology-Nephrology » Neoplasia/BPH 26. October 2026
Search
medline.ch
Neoplasia/BPH
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Inflammation-Infection
Nephrolithiasis
Renal Failure
Sexuality
Neoplasia/BPH
Others
Rect Top
Zoom: Zoom In Zoom Out

   Page 1 of 9617  Previews Next
   
   Articles 1 - 20 / 192337  
   
Exercise During Active Surveillance for Localized Low-Risk Prostate Cancer: Current Evidence and a Survivorship Framework.
Curr Oncol
Miller JA.
PMID: 42930166 [PubMed - as supplied by publisher]


Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.
N Engl J Med
Powles T, Grande E, Simone G, Gómez de Liańo A, Maruzzo M, Velho PI, Kikuchi E, Vu TQ, Popovic L, Çil T, Gravis G, Radkowski R, Hernández LRN, Cutuli HJ, Bamias A, Bauernhofer T, Pavic M, Choi YJ, Chang CH, Kitamura H, Rosenberg JE, Rowbottom J, Ho S, Gupta A, Drakaki A, VOLGA Investigators.
PMID: 42929692 [PubMed - as supplied by publisher]


Real-World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma.
Int J Urol
Tsujino T, Tamura K, Taoka R, Miyake M, Kobayashi K, Sasaki Y, Ogawa K, Tatarano S, Katayama S, Kato M, Abe Y, Oda Y, Wada K, Furukawa J, Araki M, Enokida H, Shiraishi K, Inoue K, Inamoto T, Azuma H, West Japan Uro.
PMID: 42929436 [PubMed - indexed for MEDLINE]


Population-level diagnostic and radiation treatment trends of low-risk prostate cancer.
Cancer
Monda SM, Odayar V, Yin M, Gonzalez RT, Jaime-Casas S, Hopfensperger KM, Kendrick D, Mietzel MA, Mislmani M, Zaki M, McLaughlin PW, Morgan TM, Jackson WC, Schipper MJ, Heimburger DK, Bryant AK, Pierce LJ, Borza T, Dess RT.
PMID: 42928983 [PubMed - indexed for MEDLINE]


Uncertainty-aware hybrid model for reliable navigation guidance in prostate biopsy.
Med Phys
Soormally C, Beitone C, Troccaz J, Voros S.
PMID: 42928638 [PubMed - indexed for MEDLINE]


Molecular and Immune Features of Metastatic Prostate Cancer in Hispanic and Non-Hispanic American Men.
Cancer Rep (Hoboken)
Recio-Boiles A, Deshmukh SK, Everly CJ, Wu S, Estrada-Mendizabal RJ, Heath E, McKay RR, Miranti C, Batai K, Lee BR, Chipollini J.
PMID: 42928456 [PubMed - indexed for MEDLINE]


Real-World Safety and Effectiveness of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer: Final Analysis of the RAPIT Study.
Target Oncol
Huang CY, Huang CP, Huang YY, Huang SK, Lu K, Meng E, Huang SP, Lee MY, Hung SC, Chen F, Pang ST.
PMID: 42928397 [PubMed - as supplied by publisher]


Chromophobe renal cell carcinoma: addressing the translational gap toward precision oncology for advanced disease.
J Transl Med
Lei X, Dong R, Yin L, Wu Z, Wang L, He M.
PMID: 42928313 [PubMed - indexed for MEDLINE]


Comparative diagnostic accuracy of PSMA-PET versus conventional imaging for Initial T/N/M staging of intermediate- to high-risk prostate cancer: a patient-level paired bivariate meta-analysis.
BMC Cancer
Wu H, Zhang W, Yang L, Yan X, Song P, Dong Q.
PMID: 42928137 [PubMed - indexed for MEDLINE]


Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.
Ann Oncol
Rini BI, Choueiri TK, Voss MH, Burotto M, Oldenburg J, Gurney HP, Ferguson TR, Hammers H, Albiges L, Ürün Y, Romero Diaz RI, Özgüro, Weber PY, Verzoni E, Porta C, Drakaki A, Guo J, Matsubara N, Chen A, Burgents JE, Rodriguez-Lopez KG, Powles TB.
PMID: 42927856 [PubMed - as supplied by publisher]


Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy.
Ann Oncol
Heng DYC, Schmidinger M, McDermott R, Park SH, Burotto M, Ciccarese C, Verzoni E, Suárez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, de Velasco G, Valderrama BP, Azad AA, De Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JB, Lin J, Perini RF, Vickery D, Motzer RJ, LITESPARK-011 Investigators.
PMID: 42927855 [PubMed - as supplied by publisher]


THE DOUBLE-EDGED SWORD OF ANDROGEN SIGNALING FOR SELECTIVE RADIOSENSITIZATION OF PROSTATE CANCER CELLS.
Trans Am Clin Climatol Assoc
Deweese TL, Coulter JB, Yegnasubramanian S.
PMID: 42927289 [PubMed - indexed for MEDLINE]


Prospective Clinical Evidence on Artificial Intelligence-Enabled Augmented and Mixed Reality in Robot-Assisted Prostate and Kidney Cancer Surgery: A Systematic Review.
Cureus
Harrison G.
PMID: 42927213 [PubMed]


Value of multiparametric MRI in predicting postoperative upgrading of prostate cancer with biopsy Gleason Grade Groups 3 + 3 and 3 + 4.
BJR Open
Zhang J, Zhang X, Bai X, Chen L, Guo E, Wu Y, Zhang G, Jin Z, Sun H.
PMID: 42927141 [PubMed]


Introducing higher harmonic generation microscopy for renal tumour pathology: a perspective on clinical translation.
Biophys Rev
Duijn M, Spies S, de Haan LT, de Bruin DM, Lange MM, Savci CD, van Delden OM, Groot ML, Zondervan PJ.
PMID: 42927108 [PubMed]


Fumarate Hydratase-Deficient Renal Cell Carcinoma in a Solitary Kidney: Diagnostic Pitfalls and Onco-Nephrology Constraints in an Older Adult With Chronic Kidney Disease.
Cureus
Sanka S, Mudupula Vemula SS, Kulkarni A, Koduru U, Hrinczenko B.
PMID: 42927048 [PubMed]


Peripheral and selective venous liquid biopsy profiling in localized prostate cancer: A pilot feasibility study.
J Liq Biopsy
Ricotta R, Trifirň G, Andreolli EM, Spinapolice EG, Tagliabue E, Camerota TC.
PMID: 42927017 [PubMed]


Detection of extraprostatic extension of prostate cancer by transfer learning AI models versus radiologists on biparametric and multiparametric MRI.
Res Sq
Tong A, Daniels A, Ginocchio L, Smereka P, Dutt T, Umapathy L, Nayan M, Chandarana H, Johnson P.
PMID: 42926655 [PubMed]


Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.
Nat Med
Necchi A, Mercinelli C, Maiorano BA, Piacentini M, Cigliola A, Iacovelli R, Ciccarese C, Ligato C, Giannatempo P, Rametta A, Gontero P, Soria F, Schuberth-Wagner C, Wischhusen J, Rössler B, Metterlein M, Ries S, Ross T, Amin A, Dreker T, Hermann F, Lemke L, Klar K, Mitina O, Kamova A, Fettes P, Auckenthaler A, Rao S, Leo E, Lichtenegger FS.
PMID: 42926233 [PubMed - as supplied by publisher]


Exposure to per- and polyfluoroalkyl substances and the odds of renal cell carcinoma: a case-control study.
Environ Sci Pollut Res Int
Ando S, Harada KH, Oshiro Y, Goya M, Lyu Z, Harada Sassa M, Tokuda Y.
PMID: 42925465 [PubMed - as supplied by publisher]


   
   Articles 1 - 20 / 192337    Page 1 of 9617  Previews Next

 
Rect Bottom
Adserver Footer
 

  Time frame  
   

Sky right 1